Research Roundup

OFFICIAL PUBLICATION OF

by its subsidiary APPco

Debbie Rigby 01/05/2018

Debbie Rigby takes a look at the latest in research news Comparative effectiveness of extended-release naltrexone versus buprenorphine-naloxone for opioid relapse prevention (X:BOT) A 24-week randomised controlled, comparative effectiveness trial comparing extended-release naltrexone, an opioid antagonist, and sublingual buprenorphine-naloxone, a partial opioid agonist has concluded these medicines indicated for opioid dependence are equally safe and

This content is restricted to registered users only. If you have already registered on the AJP website please login below, Or you can Register for free.

Recent Comments
Popular Posts

Will weight loss drugs eat into supermarkets’ profits?

Isn't it something positive if finally there is something that encourages people to eat less unhealthy food options. I struggle…

manal Oz

Escape the city for better pay

If what Raven Recruitment claimed ($120k salary package for a pharmacist manager in a metropolitan area) is true, it is…

Morbidly Obese John

CAPS leaders to contest Guild elections

Just found it curious that the single Carrum Downs polling booth where CAPS were active had an 8% swing away…

Michael Khoo

Vyvanse supply issues ease

In general, around 3 months late in admitting there is a shortage, and at least one month too soon in…

Michael Khoo

Research Roundup

Previous Setting the agenda

Next Mind-bending drugs and devices: can they make us smarter?

Clinical tips: Timing!

Clinical tips: Movement disorders

Clinical tips: Worms, Worms, Worms

Intranasal Midazolam for at home use

MENU

Previous Setting the agenda

Next Mind-bending drugs and devices: can they make us smarter?

Related Posts

MENU

Hi there! 👋 Looks like you’re not logged in.